Strictly adhering to the WHO/FDA recommendation, thousands of bacterial and yeast strains from ABPL culture collection were extensively screened and 134 bacterial strains and 18 yeast strains were found to be displaying antagonistic activity against wide range of gut pathogens. Out of 134 strains, 10 strains were found to be potential candidates, they exhibited greater antagonistic activity against several pathogenic bacteria and exhibited resistance to bile salts and gastric juice (low pH) and classified under putative probiotic strains. All the 10 strains are Catalase negative, Gram-positive non-spore forming rods and the strains are designated with ABPL accession numbers.

ECOTRAX, ECOTOXNIL, RHODOMAX, NOVIB etc., are some of the successful products researched and developed for shrimp and aquaculture health by ABPL research team. Continuous improvement in the process of manufacturing and the quality aspects is a constant endeavour at ABPL. Every bacterial strain that is used in these products is been tested for its stability and also periodically tested for its genetic stability.

Much of the research efforts are being now focused on the yield improvement of every probiotic bacterial strains through optimizing its nutritional requirements with special reference to developing cost effective media optimization.

Currently we manufacture probiotics for leading Indian companies like Tablets (India) Ltd, USV, Dr Reddy’s, Sun Pharma, Mankind, Lupin, Glenmark, Torrent, Fourrts India, Pharmed, Unichem etc., and Overseas companies like Sanofi, Abbott, Sunwave Pharma, Euro Lifecare, Aceto, Blis technology, etc., and also manufacture products of international probiotic giants like CHR Hansen, DuPont Nutrition, TOA pharmaceuticals, DSM, Lesaffre, UAS Labs, Morinaga etc., for their partners in Indian subcontinent at our state of the art probiotic manufacturing and research facility using Japanese technology and rigid process engineering and controls. We manufacture probiotics in form of capsules, capsule in capsule, sachets, sachet in sachet, tablets, lozenges, dry syrup and latest development is that of probiotic drops.

ABPL is now looking for strategic partners who have interest in Probiotics to have a synergistic partnership to take the research forward. We are open to different models of collaboration as well.

ABPL R&D Program

The Company’s R&D effort is focussed on three areas:

  • Developing fourth generation designer’s probiotics for human therapeutic purposes.
  • Developing probiotic therapy as an alternative for antibiotics for poultry
  • Developing water and soil probiotics for environmentally sustainable aquaculture.

ABPL Research areas

Establishment of a culture collection

This research area forms a central part of the Network. Among its objectives are isolating, characterizing, and cataloging of bacteria, yeast from various sources. Identifying the characterized strains at strain level by employing polyphasic approach (using conventional and molecular taxonomy).

Identifying putative probiotic strains

In vitro studies to investigate the following characters.

  • Its effects on the growth of various pathogens
  • Their capacity for adhering to gut cells using intestinal Caco-2 cell.
  • Their ability to reduce cholesterol and produce H2O2
  • Tolerate bile salts and gastric juice.

Safety studies and standardization of downstream production
In vitro and in vivo safety studies in animal model system and human clinical trials and standardization of fermentation and lyophilization and robust technology to sustain the stability of the bacterial strains.

Our Commitment:

ABPL is committed to conducting state-of-the-art probiotic research and development in order to be leaders in probiotic research in the area of human and livestock industries such as aquaculture, poultry and dairy.

Rationale of Our Commitment to Provision of High-Level Scientific and Clinical Data
As the market for probiotic-containing products has grown rapidly, the WHO and FAO met in 2001 to provide guidelines for standardisation of probiotics. In summary, they stated that probiotic microbes should be capable of surviving passage through the digestive tract and have the capability to proliferate, meaning they must:

  • be resistant to gastric juices (acid and bile)
  • grow in the presence of bile as in the gut
  • be able to colonise the human intestinal tract

More importantly, the organisms should be identified by strain using molecular tools.

In order to be termed a “probiotic”, the WHO/FAO also decreed that the probiotic microbe must be able to confer defined health benefits based on clinical data on the specific strain. WHO pointed out that not all probiotics are capable of meeting the criteria – therefore it is essential to define the specific strain used in trials.

Probiotic criteria

In general, it is agreed that the selection criteria for a lactic acid bacterium to be cited as a ‘probiotic’ should be :

  • non-pathogenic;
  • withstand incorporation into a delivery vehicle at high cell counts, and
  • remain viable throughout the shelf-life of the product;
  • withstand transit through the gastrointestinal tract, that is, show acid
  • and bile tolerance;
  • be able to adhere to cells of the intestinal epithelium and/or colonize the
  • lumen of the tract;
  • show antagonistic activity towards enteric pathogens and/or
  • provide demonstrated health benefits.